SUTRO BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.10 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2020-03-16
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-03-31 was $1.70M, a 750.00% increase year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-12-31 was $1.60M, a 700.00% increase year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-09-30 was $300.00K, a 50.00% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2018-03-31 was $200.00K.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $1.10M, a 52.17% decline from fiscal 2018.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $2.30M, a 43.75% increase from fiscal 2017.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $1.60M, a 77.78% increase from fiscal 2016.
- SUTRO BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $900.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2019-12-31 | $1.10M 10-K · filed 2020-03-16 | |||
| 2019-03-31 | $1.70M 10-Q · filed 2019-05-15 | $3.30M derived: sum of 2 quarters · filed 2020-03-16 | $3.60M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.90M derived: sum of 2 quarters · filed 2020-03-16 | $2.30M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $300.00K 10-Q · filed 2018-11-14 | $700.00K 10-Q · filed 2018-11-14 | ||
| 2018-03-31 | $200.00K 10-Q · filed 2019-05-15 | $400.00K derived: sum of 2 quarters · filed 2020-03-16 | $1.00M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $800.00K derived: sum of 2 quarters · filed 2020-03-16 | $1.60M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $600.00K 10-Q · filed 2018-11-14 | $1.40M 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $900.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |